Formation Bio

Formation Bio is a New York-headquartered, tech-driven and AI-native pharmaceutical company that acquires or in-licenses clinical-stage drug candidates from pharma companies, biotechs and universities and develops them internally using a proprietary technology platform. Its stated premise is that drug discovery output has outpaced the capacity of the clinical development system: development costs have risen sharply while only a fraction of candidates reach patients, leaving a backlog of potential treatments. The company positions clinical execution, rather than discovery, as the principal bottleneck it targets.

Operationally, Formation Bio runs an end-to-end model spanning research and development, in-house clinical operations (patient recruitment, site management, study monitoring) and technology. Its platform includes patient intelligence, data surveillance and a universal data layer, and the company reports streamlining study startup, participant recruitment, data management, database lock and study close-out to run trials faster than industry benchmarks. It has integrated large language models and AI applications across workflows, with near-term uses including AI-generated patient recruitment content and AI-generated adverse event reports; a medium-term goal of an 'AI R&D Scientist' for development decision support; and a longer-term aim of models predicting toxicity, tolerability and efficacy. Other cited application areas include medical writing, protocol development, biostatistics, report generation and regulatory intelligence.

As of 2024 the company had three clinical-stage candidates: treatments for chronic hand eczema (the most advanced, then recently entered Phase 3), sensory neuropathy, and knee osteoarthritis. Contrary Research reported 193 employees and Series D stage as of its January 2026 update.

Founding story

Co-founder and CEO Benjamine (Ben) Liu studied biology at Yale, completed an MPhil in computational biology at Cambridge as a Paul Mellon Fellow/Scholar, and pursued a DPhil at Oxford as a Rhodes Scholar, using machine learning, AI and big data to develop diagnostics and therapeutics for Parkinson's and Alzheimer's disease. During his graduate research he identified promising Parkinson's drug candidates but found that pharmaceutical companies declined to advance them because they lacked bandwidth and resources for additional clinical trials, leading him to conclude that the bottleneck had shifted from discovery to clinical execution. In 2016, while still completing his doctorate, he co-founded TrialSpark with Linhao Zhang and Kit Dobyns. Liu and Dobyns had been assigned as roommates during the Rhodes Scholar pre-orientation at Oxford, while Dobyns and Zhang met as roommates during a Salesforce internship. Zhang, a computer science graduate of the University of Texas at Austin, had worked as an engineer at Salesforce and Oscar Health.

Business model

Formation Bio acquires or in-licenses clinical-stage drug assets from pharmaceutical companies, biotechs and universities, then develops them in-house past clinical proof of concept and beyond, aiming to capture value at development inflection points through bespoke exit and out-licensing pathways. It operates a hub-and-spoke structure, placing each acquired asset into a standalone entity called a NewCo with a dedicated cross-functional 'pod' (clinical, CMC, data science, and others) led by a Clinical Lead and General Manager. The NewCo model can facilitate shared ownership and outcomes with partners while Formation Bio supplies the capital and capabilities needed to advance the asset. For smaller biotechs this offers a way to advance non-lead pipeline assets; for large pharma it provides an 'off balance sheet' development pathway.

Sources describe value capture through ownership and development of in-licensed or acquired clinical-stage assets, with returns realized at value inflection points via bespoke exit, out-licensing and development pathways, and through shared-ownership NewCo structures with partners; sources do not specify pricing or revenue figures.

Traction

As of 2024-2025 the company had supported hundreds of studies across the clinical trial timeline in roles ranging from recruitment vendor and technology partner to trial site manager and CRO. It reported three clinical-stage candidates in 2024 — chronic hand eczema (then recently reaching Phase 3), sensory neuropathy and knee osteoarthritis. Team and advisors have been involved in over 75 regulatory submissions (as of May 2024) and 45+ approved drugs (as of April 2025). Contrary Research reported 193 employees and total funding of $528 million as of January 2026; a June 2024 report citing PitchBook put cumulative funding above $600 million, with a Series C valuation of $1 billion and a Series D described as a material step up.

Latest developments

Mike Ehlers joined as Chief Scientific Officer and Head of R&D, per the company's website announcement banner. Contrary Research's profile, updated January 2026, lists the company as private at Series D stage with 193 employees and $528 million in total funding, and states it had supported hundreds of studies as of 2025 with team and advisors involved in over 75 regulatory submissions (May 2024) and 45+ approved drugs (April 2025). The most recent disclosed financing remains the June 2024 $372 million Series D, following the May 2024 OpenAI and Sanofi AI collaboration.